Eurofins

Articles

A panel of experts from bio/pharmaceutical companies discuss plasmids to establish specifications using a risk-based approach to manage supply, including the response to cell & gene therapy industry feedback, future outlook and re-evaluating plasmid risks.

Further Discussion on Plasmids to Establish Release Specifications Using a Risk-Based Approach to Manage Supply (Aug 2023)

The Eurofins BioPharma Product Testing (BPT) lab in Portage, MI, is expanding its capabilities in raw materials testing through collaboration with its Lancaster, PA, site. With a surge in demand for raw materials testing, BPT aims to enhance business continuity and deliver seamless services. This expansion aligns with Eurofins' commitment to meeting clients' testing demands efficiently and maintaining high-quality results.

Lancaster & Portage sites collaborate to bring new raw materials testing services to the MI facility

Eurofins BioPharma Product Testing’s Biologics Raw Materials testing team has vast experience in cell & gene therapy testing, including evaluating critical quality attributes for ancillary and raw materials.

Raw Materials Testing for Cell & Gene Therapies

No bio/pharmaceutical product can be manufactured without first establishing the identity, purity and quality of its starting materials to ensure the product is suitable for its intended use. This guide covers all testing and considerations for raw materials supported at Eurofins BioPharma Product Testing.

Your Ultimate Guide to Raw Materials Testing Support

Raw Materials Testing for Cell & Gene Therapy Manufacturing

For all stages throughout the development, manufacturing and release of your biological product, Eurofins BioPharma Product Testing offers comprehensive, fully cGMP-compliant Viral Safety Services, including characterization of cell banks, unprocessed bulk testing, end of production cells, and raw materials testing.